Loading
Outset Medical, Inc. Stock: price and insider trades · United States
1 insider bought €768k of shares over the last 90 days, the latest filed 05 Oct 2026.
Outset Medical, Inc.: what insiders have been doing
Every trade that managers of Outset Medical, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 27 filings signed by 11 insiders.
Both sides are active: 2 purchases worth €768k and 16 sales worth €199k, from 1 insider and 5 insiders respectively. Taken together, the purchases exceed the sales by €569k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Those buying include 1 major shareholder. The largest single trade was a purchase of €711k by Leonard Braden Michael, published on 5 October 2026, equal to 1.1% of the market capitalisation.
The last purchase on record was published on 5 October 2026, which is 13 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
With 27 filings in twelve months, the company is more active than the median of 19 filings across the 5,813 companies we follow on the same exchange. Looking back to 2021, when coverage begins, insiders filed 5 purchases and 138 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 119.5 m USD and net income of -81.7 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
310
Thresholds
n/a
Buy Volume
€1M
5 ops. · all time
Sell Volume
€3M
138 ops. · all time
Who traded when
BuySaleJohn L. Brottem11 sales
Leslie Trigg11 sales
Marc Nash10 sales
Ahmed Nabeel5 sales
Braden Michael Leonard2 buys
Karen Drexler1 sale
+1 other insider
Since the insiders bought
- -74.3%Entry US$299.10 · Close at T+365 US$76.95
- -44.1%Entry US$569.70 · Close at T+365 US$318.60
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Outset Medical, Inc. Buy (bullish), based on 3 analysts. Average price target: US$7.67.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 23,464 of 24,148 companies
12.0
score / 100
Value2
Quality22
FCF yld-64%
Earn yld-110%
EV/EBITDA·
ROE-59%
Gross mgn39%
Net mgn-68%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.06
Analyst consensus
3 analystsBuy
US$6.00Target US$7.67(+89%)US$10.00
Income statement
RevenueUS$119.5M
Gross profitUS$46.8M39% margin
EBITDA-US$62.6M-52% margin
Net income-US$81.7M-63.1% margin
Valuation
PER (forward)-1.8x
P/Book0.8x
Beta1.99
Balance sheet & cash
Market capUS$76.3M
Total debtUS$101.2M
Free Cash Flow-US$47.1M
Debt / Equity108%
Profitability & ownership
ROE-59.2%
ROA-15.5%
% insiders5.5%
% institutions74.9%
Last declaration on 5 October 2026
Declarations310 total
228,334 shares@ US$3.531.07% mcap92.6% of flowCommon StockSEC:0001373604-26-000050:0
Canonical exit: 30 Dec 2026 (T+90)
16,575 shares@ US$3.87580.086% mcap7.4% of flowCommon StockSEC:0001373604-26-000050:1
Canonical exit: 31 Dec 2026 (T+90)
3,437 shares@ US$4.390.026% mcap0.5% of flowCommon StockSEC:0001484612-26-000050:0
2,632 shares@ US$4.390.020% mcap0.9% of flowCommon StockSEC:0001484612-26-000048:0
4,543 shares@ US$4.390.034% mcap15.7% of flowCommon StockSEC:0001484612-26-000047:0
2,562 shares@ US$4.50790.020% mcap0.9% of flowCommon StockSEC144:0001823381-26-000009
4,422 shares@ US$4.50910.034% mcap15.7% of flowCommon StockSEC144:0001742428-26-000005
3,344 shares@ US$4.50950.026% mcap0.5% of flowCommon StockSEC144:0001304125-26-000008
59,830 sharesCommon StockSEC:0001484612-26-000045:0
71,630 sharesCommon StockSEC:0001484612-26-000043:0
10,667 shares0Common StockSEC:0001484612-26-000030:0
17,672 shares@ US$4.94480.11% mcap68.6% of flowCommon StockSEC144:0001742428-26-000001
96,000 shares0Common StockSEC:0001484612-26-000021:0
2,842 shares@ US$3.350.7% of flowCommon StockSEC:0001823381-26-000006:0
3,361 shares@ US$3.350.4% of flowCommon StockSEC:0001304125-26-000004:0
9,314 shares@ US$5.123.6% of flowCommon StockSEC:0001484612-26-000017:0
11,794 shares@ US$5.122.1% of flowCommon StockSEC:0001484612-26-000015:0
18,667 shares0Common StockSEC:0001484612-26-000007:0
224 shares@ US$4.270.1% of flowCommon StockSEC:0001484612-26-000005:0
1,795 shares@ US$4.270.3% of flowCommon StockSEC:0001484612-26-000004:0
1,548 shares@ US$4.37100.0% of flowCommon StockSEC:0001484612-25-000081:0
916 shares@ US$4.600.1% of flowCommon StockSEC:0001484612-25-000080:0
25 of 310 declarations
About Outset Medical, Inc.
Outset Medical, Inc. is a U.S.-listed medical technology company traded on the Nasdaq market in the United States (ticker: OM). The company focuses on dialysis, with a strategy centered on reducing the cost and complexity of treatment while improving the experience for patients, nurses, and care providers. Founded in 2004 and headquartered in San Jose, California, Outset is best viewed as a specialized medtech rather than a broad-based healthcare conglomerate.
Its core platform is Tablo®, a hemodialysis system designed for use across the care continuum, from hospital settings to the home. The system is positioned as a technology designed to simplify dialysis delivery through a more automated, integrated workflow. That product-centric model matters: Outset is not merely selling equipment, but a care-delivery platform that may help hospitals and renal providers insource dialysis services, potentially improving operational efficiency, staffing flexibility, and patient access.
Read moreShow less
In competitive terms, Outset operates in a dialysis market that includes established device manufacturers and large renal-care players. Its differentiation appears to rest on ease of use, portability of deployment, and the ability to support multiple points of care. The company states that Tablo is FDA-cleared for use from hospital to home, and management has said the platform is in more than 1,000 U.S. care sites and has supported millions of treatments. That level of adoption suggests meaningful commercial traction, although Outset is still in an expansion phase rather than a mature scale business.
Recent developments have been primarily operational and financial. Throughout 2025, the company reported quarterly updates showing modest revenue growth and improving operating efficiency, alongside continued efforts to control cash burn. In January 2026, Outset disclosed that more than 1,000 sites of care had insourced dialysis with the company, with roughly 1 million treatments per year and more than 3 million cumulative Tablo treatments. It also announced the appointment of Karen N. Prange to its board of directors. For international investors, Outset remains a focused growth medtech exposure to the U.S. dialysis market, with an innovation-led thesis and the usual execution risks associated with scaling a specialized medical device platform.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
